Centocor Ortho Biotech Inc. Acquires RespiVert Ltd., Strengthens Pulmonary Focus

Acquisition Bolsters Pulmonary Portfolio and Capabilities, Accessing Promising Pipeline of First-in-Class Compounds and Renowned Team of Respiratory Scientists

HORSHAM, Pennsylvania, June 1, 2010 - Centocor Ortho Biotech Inc. today announced that it has acquired
RespiVert Ltd., a privately held drug discovery company focused on developing
small-molecule, inhaled therapies for the treatment of pulmonary diseases.
The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase
inhibitors with a unique profile of anti-inflammatory activities, are
progressing into clinical development as potential first-in-class treatments
for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD)
and Cystic Fibrosis (CF). The clinical development of RV-568 and RV-1088 will
be led by RespiVert in collaboration with scientists at Centocor Research and
Development, Inc. The company is not disclosing financial terms.

"The RespiVert compounds offer the potential for a new class of medicines
for patients with severe lung disease who are insensitive to inhaled
corticosteroids," said Susan Dillon, Ph.D., Global Therapeutic Area Head,
Immunology, Centocor Research and Development, Inc. "The addition of
RespiVert's expert scientific team and discovery platforms for inhaled
medicines strengthens our capabilities and further builds our pipeline of
novel oral and biologic therapies for serious pulmonary diseases."

With the acquisition of RespiVert, Centocor Ortho Biotech gains a
portfolio of first-in-class, early-stage inhaled treatments for serious lung
diseases. RespiVert will continue to maintain its research and discovery
presence in London from the Imperial BioIncubator, which is based at the
campus of Imperial College London. RespiVert employees will continue to lead
ongoing research and drug discovery efforts.

Dr. Garth Rapeport, Chief Executive Officer of RespiVert
(www.respivert.com/), who is remaining with RespiVert following the
acquisition, said, "We believe that our focused discovery efforts in
pulmonary disease offer a unique opportunity to bring completely new
treatment options to patients who suffer from severe, chronic respiratory
diseases including Chronic Obstructive Pulmonary Disease, severe asthma and
Cystic Fibrosis."

About Asthma, COPD, and CF

Severe or uncontrolled asthma is associated with significant morbidity,
resulting in missed work and school days, and substantial limitation of
activity, adversely impacting quality of life in asthmatics. Severe asthma
represents a particular societal burden, with sources suggesting that half of
the total cost of asthma in the United States is attributable to severe
disease. Asthma is the cause of over 4,000 deaths each year in the U.S. and
over 12,000 in Europe.

COPD (www.respivert.com/disease-focus.aspx) is an umbrella term
for a group of lung diseases which include chronic bronchitis, emphysema and
small airways disease. COPD is a serious, chronic disorder characterized by a
slowly progressive decline in lung function with symptoms such as chronic
cough and dyspnea significantly impacting quality of life. COPD is estimated
to cause 130,000 deaths per year in the U.S.

CF (www.respivert.com/disease-focus.aspx) is an inherited
life-threatening disease involving a genetic mutation that disrupts the
cystic fibrosis transmembrane regulator (CFTR) protein, resulting in poorly
hydrated, thickened mucous secretions in the lungs and digestive tract. Due
to these changes, the lungs of individuals with cystic fibrosis are colonized
and infected by bacteria from an early age. This leads to progressive and
severe lung inflammation which is difficult to treat.

About Centocor Ortho Biotech Inc.

Centocor Ortho Biotech Inc. redefines the standard of care in immunology,
nephrology and oncology. The company was formed when Centocor, Inc. and Ortho
Biotech Inc. were consolidated in late 2008, and was renamed Centocor Ortho
Biotech Inc. Built upon a pioneering history, Centocor Ortho Biotech Inc.
harnesses innovations in large-molecule and small-molecule research to create
important new therapeutic options. Beyond its innovative medicines, Centocor
Ortho Biotech is at the forefront of developing education and public policy
initiatives to ensure patients and their families, caregivers, advocates and
healthcare professionals have access to the latest treatment information,
support services and quality care. For more information about Centocor Ortho
Biotech, visit www.CentocorOrthoBiotech.com. Centocor Ortho Biotech
Inc. and Centocor Research and Development Inc. are wholly-owned subsidiaries
of Johnson & Johnson.

About RespiVert

RespiVert is a small molecule drug discovery company working towards the
identification of new treatments for patients with Chronic Obstructive
Pulmonary Disease (COPD), Cystic Fibrosis (CF) and severe asthma. The more
severe forms of these diseases are poorly responsive to existing therapies
such as inhaled corticosteroids and new disease modifying treatments are
urgently required. RespiVert has been financed by Advent Venture Partners,
Fidelity Biosciences, Imperial Innovations and SV Life Sciences.

Forward-looking statements

(This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Centocor Ortho Biotech Inc.'s and/or
Johnson & Johnson's expectations and projections. Risks and uncertainties
include general industry conditions and competition; economic conditions,
such as interest rate and currency exchange rate fluctuations; technological
advances and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approvals; domestic and
foreign health care reforms and governmental laws and regulations; and trends
toward health care cost containment. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson
& Johnson's Annual Report on Form 10-K for the fiscal year ended January 3,
2010. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake
to update any forward-looking statements as a result of new information or
future events or developments.)

Media: Brian Kenney, +1-215-325-2107 (o), +1-215-620-0111 (m), or Bill Price, +1-732-524-6623 (o), +1-732-668-3735 (m); or Investors: Louise Mehrotra, +1-732-524-6491 (o) or Tina Pinto, +1-732-524-2034 (o)